173 related articles for article (PubMed ID: 3301517)
1. Hemodynamic evaluation of isosorbide dinitrate in alcoholic cirrhosis. Pharmacokinetic-hemodynamic interactions.
Blei AT; Garcia-Tsao G; Groszmann RJ; Kahrilas P; Ganger D; Morse S; Fung HL
Gastroenterology; 1987 Sep; 93(3):576-83. PubMed ID: 3301517
[TBL] [Abstract][Full Text] [Related]
2. Effects of isosorbide dinitrate on portal hypertension in alcoholic cirrhosis.
Merkel C; Finucci G; Zuin R; Bazzerla G; Bolognesi M; Sacerdoti D; Gatta A
J Hepatol; 1987 Apr; 4(2):174-80. PubMed ID: 3584925
[TBL] [Abstract][Full Text] [Related]
3. Lack of effects of isosorbide-5-mononitrate on hepatic hemodynamics in HBsAg-positive cirrhosis.
Tsai YT; Lee FY; Lin HC; Chang TT; Lay CS; Wang SS; Kong CW; Lee SD; Lo KJ
Hepatology; 1989 Sep; 10(3):283-7. PubMed ID: 2759546
[TBL] [Abstract][Full Text] [Related]
4. Treatment of portal hypertension with isosorbide dinitrate alone and in combination with vasopressin.
Hallemans R; Naeije R; Mols P; Mélot C; Reding P
Crit Care Med; 1983 Jul; 11(7):536-40. PubMed ID: 6861502
[TBL] [Abstract][Full Text] [Related]
5. Reduction of portal pressure by chronic administration of isosorbide dinitrate in patients with cirrhosis: effects on systemic and splanchnic hemodynamics and liver function.
Ikegami M; Toyonaga A; Tanikawa K
Am J Gastroenterol; 1992 Sep; 87(9):1160-4. PubMed ID: 1519573
[TBL] [Abstract][Full Text] [Related]
6. Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic haemodynamics in patients with cirrhosis.
Escorsell A; Feu F; Bordas JM; García-Pagán JC; Luca A; Bosch J; Rodés J
J Hepatol; 1996 Apr; 24(4):423-9. PubMed ID: 8738728
[TBL] [Abstract][Full Text] [Related]
7. Hemodynamic effects of combined treatment with somatostatin analogue (SMS 201-995) and low-dose isosorbide dinitrate on portal hypertension in conscious cirrhotic rats.
Hori N; Okanoue T; Sawa Y; Itoh Y; Mori T; Takami S; Kashima K
J Gastroenterol; 1994 Aug; 29(4):460-8. PubMed ID: 7951857
[TBL] [Abstract][Full Text] [Related]
8. Different haemodynamic effects of a single dose of long-acting isosorbide-5-mononitrate in healthy subjects and patients with cirrhotic portal hypertension.
Piscaglia F; Donati G; Gaiani S; Gramantieri L; Leoni S; Mancini M; Bolondi L
Dig Liver Dis; 2004 Sep; 36(9):594-602. PubMed ID: 15460844
[TBL] [Abstract][Full Text] [Related]
9. Systemic and regional hemodynamic effects of isosorbide dinitrate in patients with liver cirrhosis and portal hypertension.
Mols P; Hallemans R; Melot C; Lejeune P; Naeije R
J Hepatol; 1989 May; 8(3):316-24. PubMed ID: 2732445
[TBL] [Abstract][Full Text] [Related]
10. Hemodynamic effects of isosorbide dinitrate vs nitroglycerin in patients with unstable angina.
Willis WH; Russell RO; Mantle JA; Ratshin RA; Rackley CE
Chest; 1976 Jan; 69(1):15-22. PubMed ID: 811427
[TBL] [Abstract][Full Text] [Related]
11. [Hemodynamic and functional hepatic effects of isosorbide-5-monitrate in cirrhotic patients with portal hypertension].
Silva G; Fluxá F; Ruiz M; Bresky G; Barrientos C; Backhouse C; Palma M; Iturriaga H
Rev Med Chil; 1993 Aug; 121(8):889-96. PubMed ID: 8296096
[TBL] [Abstract][Full Text] [Related]
12. Vascular hyporeactivity persists despite increased contractility after long-term administration of isosorbide dinitrate in portal hypertensive rats.
Huang YT; Lin HC; Tsai JF; Hou MC; Lee SD; Hong CY
J Hepatol; 1998 Jun; 28(6):1037-44. PubMed ID: 9672181
[TBL] [Abstract][Full Text] [Related]
13. Influence of systemically given placebo, trapidil and isosorbide dinitrate on norepinephrine-evoked hand vein constriction in healthy subjects.
Sziegoleit W; Dannenberg K; Konschak A; Lautenschläger C; Presek P
Arzneimittelforschung; 2007; 57(2):81-6. PubMed ID: 17396617
[TBL] [Abstract][Full Text] [Related]
14. Nitrate tolerance: hemodynamic effects of intravenous isosorbide dinitrate after sustained oral isosorbide dinitrate administration.
Kumagae H; Koiwaya Y; Tanaka K
Clin Ther; 1990; 12(1):31-43. PubMed ID: 2328526
[TBL] [Abstract][Full Text] [Related]
15. Effects of 5-isosorbide mononitrate and propranolol on subclinical hepatic encephalopathy and renal function in patients with liver cirrhosis.
Silva G; Segovia R; Ponce R; Backhouse C; Palma M; Roblero JP; Abadal J; Quijada C; Troncoso M; Iturriaga H
Hepatogastroenterology; 2002; 49(47):1357-62. PubMed ID: 12239942
[TBL] [Abstract][Full Text] [Related]
16. The acute and chronic effects of isosorbide-5-mononitrate on portal haemodynamics in cirrhosis.
Grose RD; Plevris JN; Redhead DN; Bouchier IA; Hayes PC
J Hepatol; 1994 Apr; 20(4):542-7. PubMed ID: 8051395
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic effects of oral isosorbide-5-mononitrate and dinitrate in ischemic heart failure.
Rabinowitz B; Hod H; Chouraqui P; Rath S; Agranat O; Neufeld HN
Clin Cardiol; 1987 Oct; 10(10):603-8. PubMed ID: 3665218
[TBL] [Abstract][Full Text] [Related]
18. Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension.
García-Pagán JC; Feu F; Navasa M; Bru C; Ruiz del Arbol L; Bosch J; Rodés J
J Hepatol; 1990 Sep; 11(2):189-95. PubMed ID: 2123914
[TBL] [Abstract][Full Text] [Related]
19. Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients: long-term hemodynamic and renal effects.
Vorobioff J; Picabea E; Gamen M; Villavicencio R; Bordato J; Bessone F; Tanno H; Palazzi J; Sarano H; Pozzoli L
Hepatology; 1993 Sep; 18(3):477-84. PubMed ID: 8359793
[TBL] [Abstract][Full Text] [Related]
20. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function.
Navasa M; Chesta J; Bosch J; Rodés J
Gastroenterology; 1989 Apr; 96(4):1110-8. PubMed ID: 2925055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
